Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
Public ClinicalTrials.gov record NCT00948142. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections
Study identification
- NCT ID
- NCT00948142
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Arrevus Inc.
- Industry
- Enrollment
- 198 participants
Conditions and interventions
Conditions
Interventions
- CEM-102 Drug
- Linezolid Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2009
- Primary completion
- Feb 28, 2010
- Completion
- Feb 28, 2010
- Last update posted
- Apr 18, 2019
2009 – 2010
United States locations
- U.S. sites
- 16
- U.S. states
- 7
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Chula Vista | California | 91911 | — |
| Not listed | La Mesa | California | 91942 | — |
| Not listed | Los Angeles | California | 90015 | — |
| Not listed | Oceanside | California | 92056 | — |
| Not listed | Oxnard | California | 93030 | — |
| Not listed | Pasadena | California | 91105 | — |
| Not listed | Santa Ana | California | 92701 | — |
| Not listed | Torrance | California | 90501 | — |
| Not listed | Torrance | California | 90509 | — |
| Not listed | Columbus | Georgia | 31904 | — |
| Not listed | Savannah | Georgia | 31406 | — |
| Not listed | Springfield | Illinois | 62701 | — |
| Not listed | Detroit | Michigan | 48202 | — |
| Not listed | Butte | Montana | 59701 | — |
| Not listed | Somers Point | New Jersey | 08244 | — |
| Not listed | Akron | Ohio | 44304 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00948142, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 18, 2019 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00948142 live on ClinicalTrials.gov.